Insulin

Insulin is a 51-amino-acid heterodimeric peptide comprising an A-chain (21 amino acids) and a B-chain (30 amino acids) linked by two disulfide bridges. It exerts its metabolic effects through a well-characterized receptor-mediated signaling cascade.

• Binds the insulin receptor (IR), a transmembrane tyrosine kinase expressed abundantly on hepatocytes, skeletal muscle, and adipocytes, inducing receptor autophosphorylation on cytoplasmic tyrosine residues. • Activated IR phosphorylates insulin receptor substrates (IRS-1, IRS-2), engaging phosphatidylinositol 3-kinase (PI3K) and its downstream effector Akt, which drives translocation of GLUT4 glucose transporter vesicles to the plasma membrane—the primary mechanism of insulin-stimulated glucose uptake in skeletal muscle and adipose tissue. • In the liver, insulin suppresses gluconeogenesis and glycogenolysis (reducing fasting hepatic glucose output) while promoting glycogen synthesis. • In adipose tissue, insulin inhibits hormone-sensitive lipase, suppressing lipolysis and lowering circulating free fatty acids; it simultaneously promotes triglyceride synthesis. • Insulin inhibits protein catabolism and promotes amino acid uptake and protein synthesis in muscle.

Analog modifications exploit the B26-B30 region of the B-chain, which is not required for insulin receptor recognition, to alter hexameric self-association. Rapid-acting analogs are engineered to dissociate quickly from hexamers into absorbable monomers; long-acting analogs incorporate fatty acid acylation (detemir, degludec), isoelectric microprecipitation (glargine), or multihexamer formation (degludec) to produce protracted, relatively peakless absorption profiles.

The clinical evidence base for insulin is among the most extensive in medicine, anchored by landmark randomized controlled trials.

The Diabetes Control and Complications Trial (DCCT, 1983–1993) enrolled 1,441 individuals aged 13–39 with type 1 diabetes at 29 centers in the United States and Canada. Participants were randomized to intensive insulin therapy (three or more daily injections or continuous subcutaneous infusion, targeting HbA1c near the nondiabetic range) or conventional care (one to two daily injections). Over a mean follow-up of 6.5 years, intensive therapy achieved a median HbA1c of 7% versus 9% in the conventional group. Intensive therapy reduced the risk of retinopathy by 76%, nephropathy by 50%, and neuropathy by 60%. The trial was halted one year early due to the uniform magnitude of benefit. Long-term follow-up in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, tracking more than 96% of surviving DCCT participants, demonstrated persistence of these benefits: after 20 or more years, early intensive control was associated with a 30% reduction in cardiovascular events and 33% lower mortality.

The UK Prospective Diabetes Study (UKPDS 33, 1998) enrolled 3,867 newly diagnosed patients with type 2 diabetes across 23 UK centers, randomizing them to intensive glycemic control with sulfonylureas or insulin versus conventional diet-based management over a median of 10 years. Intensive therapy achieved a median HbA1c of 7.0% versus 7.9% and reduced the aggregate microvascular endpoint by 25% (RR 0.75; 95% CI 0.60–0.93). No significant benefit on macrovascular outcomes was detected in the primary follow-up period.

Meta-analyses of randomized trials comparing long-acting analogs (glargine, detemir) with NPH insulin consistently demonstrate reduced nocturnal hypoglycemia with analogs, with similar or modestly superior HbA1c reductions, supporting their preferential use in basal insulin regimens.

Typical dosage: Highly individualized; type 1 diabetes basal-bolus regimens typically require 0.5–1.0 units/kg/day total; type 2 diabetes is often initiated with basal insulin at 10 units or 0.1–0.2 units/kg/day, titrated to individual glycemic targets (Once daily (long-acting basal analogs) to four or more times daily (basal-bolus or continuous subcutaneous insulin infusion); prandial doses given 0–15 minutes before meals for rapid-acting analogs or 30 minutes before meals for regular human insulin).

Dosing is individualized based on diabetes type, body weight, insulin sensitivity, carbohydrate intake, physical activity, and concurrent medications. The following describes established clinical approaches.

Basal-bolus replacement (type 1 diabetes): Total daily dose is typically 0.5–1.0 units/kg/day, divided with approximately 40–50% as a once-daily long-acting analog (glargine, detemir, or degludec) and 50–60% split as prandial rapid-acting analog (lispro, aspart, or glulisine) given 0–15 minutes before each meal. Prandial doses are refined using an insulin-to-carbohydrate ratio (calculated as 500 divided by total daily dose) and a correction factor for out-of-range glucose (1800 divided by total daily dose, in mg/dL per unit).

Basal-only initiation (type 2 diabetes): A long-acting insulin analog is begun at 10 units or 0.1–0.2 units/kg at bedtime, titrated upward by 2–4 units every 2–3 days until fasting glucose reaches the individualized target, typically 80–130 mg/dL.

Regular human insulin (pre-meal use): Administered subcutaneously 30 minutes before a meal; dosing based on meal size, current glucose level, and provider-directed protocol.

NPH insulin: Typically dosed twice daily, with morning and evening meals or at bedtime, to provide intermediate-duration basal coverage.

Continuous subcutaneous insulin infusion (pump therapy): Uses only rapid-acting analog with individually programmed basal rates and calculated mealtime bolus doses; advanced systems integrate continuous glucose monitoring for semi-autonomous adjustment.

This information is educational in nature and does not constitute medical advice. Insulin dosing must be individualized, initiated, and supervised by a qualified healthcare provider; errors in dosing can cause severe or life-threatening hypoglycemia.

Insulin is routinely used alongside other antihyperglycemic agents and diabetes technologies to optimize outcomes.

Metformin: Standard co-therapy in type 2 diabetes; reduces hepatic glucose production and modestly lowers insulin requirements, partially offsetting insulin-associated weight gain without adding hypoglycemia risk.

GLP-1 receptor agonists (e.g., semaglutide, dulaglutide, liraglutide): Provide glucose-dependent insulin secretion stimulation and glucagon suppression, allowing reductions in basal insulin dose while improving postprandial control and promoting weight loss. Fixed-ratio co-formulations combining basal insulin with a GLP-1 agonist (insulin degludec/liraglutide as IDegLira; insulin glargine/lixisenatide as IGlarLixi) are FDA-approved and reduce injection burden.

SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin): Add insulin-independent urinary glucose excretion and reduce insulin dose requirements in type 2 diabetes; use with caution in type 1 due to elevated risk of euglycemic diabetic ketoacidosis.

Continuous glucose monitoring (CGM) and automated insulin delivery systems: Paired with insulin regimens to enable real-time dosing adjustments; closed-loop systems integrating CGM with an insulin pump reduce hypoglycemia burden and improve HbA1c.

Insulin is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Hypoglycemia, weight gain, injection-site lipohypertrophy, rare hypersensitivity reactions, peripheral edema at initiation

Hypoglycemia is the most common and clinically significant adverse effect of insulin therapy across all formulations. Severe hypoglycemia—defined as an episode requiring assistance from another person—is estimated to contribute to death in 4–10% of patients with type 1 diabetes over a lifetime. The DCCT documented a threefold increase in severe hypoglycemia with intensive versus conventional therapy, though long-term follow-up did not demonstrate lasting cognitive impairment attributable to hypoglycemia. Long-acting analogs (glargine, detemir, degludec) substantially reduce nocturnal hypoglycemia compared with NPH insulin in randomized trials.

Weight gain is common. In the DCCT, intensive insulin therapy produced an average weight gain of 4.6 kg over 6.5 years. In UKPDS, insulin-treated patients gained approximately 4.0 kg versus conventional management. Insulin detemir is associated with modestly less weight gain than glargine or NPH in comparative studies.

Injection-site lipohypertrophy—subcutaneous fat accumulation from repeated injections at the same site—impairs insulin absorption unpredictably and is prevented by systematic site rotation. Lipoatrophy is rare with modern highly purified formulations.

Early observational data raised concern regarding insulin glargine and cancer risk due to its relatively elevated IGF-1 receptor binding affinity in vitro. Subsequent data from the ORIGIN randomized trial (more than 12,500 participants) and multiple meta-analyses found no increased cancer incidence with glargine versus comparators, and no regulatory agencies have issued label changes based on this signal.

Peripheral edema and hypokalemia may occur at therapy initiation, particularly when severe hyperglycemia is rapidly corrected. Rare systemic hypersensitivity reactions have been reported with all insulin formulations.